Impact of LX4211, a Dual Inhibitor of Sodium Glucose Transporter 1 and 2, on Cardiovascular Risk Factors in Type 2 Diabetes - Impact of LX4211


The goal of this dose-ranging trial was to evaluate treatment with LX4211, a dual inhibitor of sodium glucose transporter 1 and 2, among poorly controlled type 2 diabetic patients compared with placebo.

These transporters are responsible for gastrointestinal glucose absorption and renal glucose reabsorption, respectively.